‘Transformational' new breast cancer drug could halt the growth of tumours
A new drug has been shown to halt the growth of certain breast cancer tumours, potentially delaying the need for chemotherapy, according to a new study.
The Serena-6 trial found that camizestrant is effective in stopping cancer cells from using hormones to grow. One professor described the drug as representing "a pivotal moment in breast cancer care".
Scientists said the trial marked the first global study demonstrating that early detection of cancer resistance through blood tests can significantly benefit patients.
The study focused on patients with hormone-positive, HER2-negative breast cancer, which accounts for approximately 70 per cent of all cases. The results indicated that patients treated with camizestrant experienced a 56 per cent reduction in cancer progression compared to those receiving standard therapies.
Doctors used a blood test to identify changes in the cancer's DNA, which signal the potential failure of current treatments. Upon detecting these signs, some patients were administered camizestrant, while others continued with their standard treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1 per cent stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said.
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
19 minutes ago
- Medscape
Durvalumab Plus FLOT Improves Early Upper-GI Cancer
Adding the immune checkpoint inhibitor durvalumab (Imfinzi) to the standard chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improved event-free survival (EFS) in patients with resectable, early–stage adenocarcinoma of the upper-gastrointestinal (GI) tract. Experts say these interim results, which were presented by Yelena Janjigian, MD, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago, make the case for a new standard for treating these cancers. The phase 3 MATTERHORN study 'supports the global adoption of perioperative durvalumab plus FLOT for patients with localized gastric and gastroesophageal junction adenocarcinoma,' said Janjigian of the Memorial Sloan Kettering Cancer Center in New York City at the plenary session of the meeting. The study was published simultaneously in The New England Journal of Medicine . The goal of the study is to address the low cure rates for early-stage gastroesophageal cancer, which remain below 50% with most recurrences occurring within 2 years after surgery, said Janjigian, who is also an author of the new paper. MATTERHORN enrolled 948 people with stage II, III and IVA resectable gastric cancer and gastroesophageal junction cancer, randomizing them to two regimens: Durvalumab 1500 mg plus FLOT before surgery, followed by two cycles of durvalumab 1500 mg every 4 weeks plus FLOT, and then 10 cycles of durvalumab 1500 mg every 4 weeks; or placebo plus FLOT before surgery, and then two cycles of placebo plus FLOT followed by 10 cycles of placebo. Applying Immunotherapy in Early-Stage Disease 'We know that immunotherapy works for stage IV disease in an advanced setting,' Janjigian said at a press conference before the plenary session. 'In metastatic disease, we've been using anti-PD-1 agents for years, but they have not been proven to help patients with early-stage cancer.' In MATTERHORN, patients in the durvalumab group had a 29% relative risk reduction in 2-year EFS, which was the primary endpoint. That risk reduction was 67.4% for the treatment group vs 58.5% for the placebo group ( P <.001), Janjigian said at the plenary session. Because the results are interim, the median EFS with durvalumab was not reached, which means that more than half of the patients in the durvalumab plus FLOT group had not had a cancer recurrence at 2 years. The median EFS for the placebo group was 32.8 months. Among secondary endpoints, 2-year overall survival was 75.7% in the durvalumab group vs 70.4% in the placebo group, a 22% advantage for the former, Janjigian said, but that has not yet reached statistical significance in the interim analysis. The median overall survival rate has not yet been reached because there have not been enough deaths in that group to calculate it, Janjigian told Medscape Medical News . In the placebo group, 2-year overall survival was 47.2 months. 'Survival data will continue to be followed and will be updated,' she said. 'There was a consistent event-free survival benefit with the addition of durvalumab across all subgroups, including patients aged 65 or older, patients enrolled in Asia, and patients with anti-PDL-1 and PDL-1- negative and gastroesophageal junction tumors,' Janjigian said at the plenary session. About 19% of the study participants were in Asia, 53% in Europe, 19% in South America, and 9% in North America. 'All hazard ratio estimates for the subgroups were < 1, reinforcing the consistency and robustness of the treatment effect,' Janjigian said. Safety outcomes were similar in both the durvalumab and placebo groups, Janjigian said. 'Grade 3 and 4 treatment-related adverse events occurred in 60% of patients in the durvalumab arm and 59% in the placebo arm,' she said. Grade 3 or 4 immune-mediated adverse events occurred more frequently in patients in the durvalumab group, she added: 7% vs 4%. The addition of durvalumab did not interfere with the delivery of FLOT in the perioperative setting, and, in the adjuvant phase, 52% of patients in the durvalumab group completed 1 year of therapy, as did 51% of patients in the placebo group, she said. A New Standard? 'To put it simply, the MATTERHORN trial moves the field forward and establishes perioperative durvalumab plus FLOT as the new standard for this patient population,' Samuel Klempner, MD, director of Gastroesophageal Medical Oncology and associate professor at Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, said in comments as the discussant at the plenary session. 'While overall survival is immature, I'm very optimistic that MATTERHORN will show a statistical improvement in overall survival based on the shape of the curves, the strong statistical design, and observations from other phase 3 perioperative gastric trials like RESOLVE and PRODIGY, where longer follow-up improved the hazard ratio and enhanced the significance of the P value,' Klempner said. The RESOLVE trial confirmed the survival advantage of perioperative-S-1 and oxaliplatin (SOX) and adjuvant-SOX compared with the standard adjuvant-postoperative capecitabine-and-oxaliplatin regimen in gastric or gastroesophageal junction cancer. The PRODIGY trial found that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 chemotherapy improved progression-free survival over surgery followed by adjuvant S-1 for patients with resectable locally advanced gastric cancer. The MATTERHORN population 'looks like patients in the clinic,' and the similarity in patient dispositions between the study groups was important, said Klempner. 'To me, this says that academic and community oncologists and our surgical colleagues can feel confident that adding durvalumab to FLOT does not impact our ability to complete neoadjuvant FLOT, get to surgery, achieve our zero resection, or complete adjuvant therapy,' he said. 'I also want to stake the claim for D-FLOT as the name for this new standard regimen,' he added to loud applause in the session. 'This is a pivotal trial in upper GI cancer patients in a space that's really been taking center stage in recent years with many recent advances,' Pamela Kunz MD, PhD, director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center in New Haven, Connecticut, said at a press conference before the presentation. 'This is going to change the standard of care for this patient population.' She added that physicians must carefully select patients for durvalumab plus FLOT treatment. 'Can all patients tolerate a four-drug treatment?' Kunz asked. 'The study demonstrated it was reasonably well tolerated, but in terms of the patients in front of us, we need to think about them.' This study was funded by AstraZeneca. Janjigian reported disclosed financial relationships with AbbVie, AmerisourceBergen, Arcus Biosciences, Ask-Gene Pharma, Astellas Pharma, AstraZeneca, Basilea Pharmaceutica, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, eChinaHealth, ED MedResources, EISAI, Eli Lilly and Co., Genentech, Geneos Therapeutics, GlaxoSmithKline, Guardant Health, H.C. Wainwright & Co., Imedex, Imugene, Inspirna, Lynx Health, Merck, Merck Serono, Mersana Therapeutics, Pfizer, Sanofi Genzyme, Seagen, Silverback Therapeutics, Transcenta, and Zymeworks. Klempner reported relationships with Nuvalent, Merck Serano, Amgen, Astellas Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo UCB Japan, Eisai, Elevation Oncology, Gilead Sciences, I-Mab, Merck, Novartis, SERVIER, Taiho Oncology, Arcus Biosciences, Leap Therapeutics, and Mersana. Disclosures for Kunz were not available at press time.
Yahoo
3 hours ago
- Yahoo
Nationals and Cubs meet to decide series winner
Chicago Cubs (38-23, first in the NL Central) vs. Washington Nationals (29-32, third in the NL East) Washington; Thursday, 6:45 p.m. EDT PITCHING PROBABLES: Cubs: Drew Pomeranz (2-0, 0.00 ERA, 0.51 WHIP, 15 strikeouts); Nationals: Jake Irvin (5-1, 3.93 ERA, 1.17 WHIP, 47 strikeouts) Advertisement BETMGM SPORTSBOOK LINE: Cubs -145, Nationals +121; over/under is 9 1/2 runs BOTTOM LINE: The Washington Nationals and Chicago Cubs play on Thursday with the three-game series tied 1-1. Washington has gone 14-15 in home games and 29-32 overall. The Nationals have a 13-22 record in games when they have allowed at least one home run. Chicago has a 38-23 record overall and an 18-12 record on the road. The Cubs have a 34-8 record in games when they record at least eight hits. Thursday's game is the third time these teams meet this season. TOP PERFORMERS: James Wood has 16 doubles and 16 home runs while hitting .283 for the Nationals. Josh Bell is 10 for 33 with three home runs over the past 10 games. Advertisement Kyle Tucker has 10 doubles, four triples and 12 home runs while hitting .283 for the Cubs. Michael Busch is 10 for 27 with two triples and two home runs over the last 10 games. LAST 10 GAMES: Nationals: 6-4, .246 batting average, 3.84 ERA, outscored opponents by 10 runs Cubs: 7-3, .249 batting average, 3.10 ERA, outscored opponents by 10 runs INJURIES: Nationals: Jacob Young: 10-Day IL (shoulder), Dylan Crews: 10-Day IL (back), Paul DeJong: 10-Day IL (face), Orlando Ribalta: 15-Day IL (biceps), Derek Law: 15-Day IL (forearm), DJ Herz: 60-Day IL (elbow), Mason Thompson: 60-Day IL (elbow), Josiah Gray: 60-Day IL (elbow) Advertisement Cubs: Kyle Tucker: day-to-day (finger), Miguel Amaya: 10-Day IL (oblique), Porter Hodge: 15-Day IL (oblique), Tyson Miller: 60-Day IL (hip), Eli Morgan: 60-Day IL (elbow), Shota Imanaga: 15-Day IL (leg), Javier Assad: 60-Day IL (oblique), Justin Steele: 60-Day IL (elbow) ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar.
Yahoo
8 hours ago
- Yahoo
Menopause Drug Reduces Breast Cancer Growth In Clinical Trial
A drug used to relieve the debilitating symptoms of menopause may also be reducing the risk of invasive breast cancer, a new clinical trial by Northwestern University suggests. Almost 60,000 women a year are diagnosed with a contained form of breast cancer that can indicate a higher risk of developing invasive tumors later in life. The non-invasive cancer is typically detected during routine mammograms, accounts for up to 25 percent of all breast cancer diagnoses, and has a 98 percent recovery rate after 10 years when removed by surgery. However, to increase their chance of remaining cancer-free many patients also undergo treatments like radiation and hormone therapy following surgery. These treatments often have debilitating side effects. The phase two clinical trial recruited 141 postmenopausal women who have a form of contained breast cancer called ductal carcinoma tumors. Half of them were given a medication for managing symptoms of menopause called Duavee; others were administered a placebo for the month between diagnosis and breast cancer surgery. Duavee is composed of estrogen hormones and bazedoxifene – a molecule that either promotes or dampens the use of estrogens in the body, depending on the type of tissue it is in. This estrogen receptor modifier is also used to help treat osteoporosis. Those who took the drug had notably less cell growth in their breast tissue by their surgery date. There was also "no impact on quality of life compared to placebo." "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," says Northwestern University surgeon Swati Kulkarni. Significantly, trial participants taking Duavee did not experience the intolerable side effects associated with other cancer drugs. Rather, it tends to increase the quality of life in people already struggling with menopause. While larger studies are still needed to confirm Duavee's ability to prevent breast cancer, Kulkarni and team suggest that, for now, those with elevated risk for breast cancer as well as menopausal symptoms would most likely benefit from Duavee. Especially given women with prior cancer lesions can't resort to hormone treatments to ease their menopause symptoms because they can increase the risk of breast cancer returning. "These results support consideration that [Duavee] is a safe option to manage menopausal symptoms for women concerned about their risk of developing breast cancer, and provide supportive evidence that [Duavee] may reduce the risk of developing invasive breast cancer," the researchers conclude in their conference abstract. The trial results have yet to be published but were presented at the American Society of Clinical Oncology's latest annual meeting. Bowel Cancer in Young People Is Rising – Here's How to Reduce Your Risk Why Do Some People Need Less Sleep? The Answer Lies in Our Genes. Regular Exercise Reduces Death From Colon Cancer by 37%, Study Finds
